Key result
Adjunctive treatment with cilostazol may more effectively overcome clopidogrel resistance in T2DM patients than doubling clopidogrel dosage during PCI.
Why the study?
Does adjunctive treatment with cilostazol improve platelet function profiles compared to clopidogrel doubling in T2DM patients undergoing a percutaneous coronary intervention?
Does adjunctive treatment with cilostazol improve platelet function profiles compared to clopidogrel doubling in T2DM patients undergoing a percutaneous coronary intervention?
Adding cilostazol to standard DAPT may be more effective than doubling the clopidogrel dose to overcome clopidogrel resistance in patients with T2DM undergoing PCI.
May inform antiplatelet strategies in clopidogrel-resistant T2DM PCI; hypothesis-generating and should not yet change practice.
Adjunctive treatment with cilostazol in T2DM patients on standard dual antiplatelet therapy might be a more effective strategy for overcoming clopidogrel resistance than clopidogrel doubling treatment.
No takes yet. Share an insight, caveat, or question.
Ha et al. (2013) studied this question. Adjunctive treatment with cilostazol may more effectively overcome clopidogrel resistance in T2DM patients than doubling clopidogrel dosage during PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: